152 related articles for article (PubMed ID: 22634531)
81. Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
Tan AR; Johannes H; Rastogi P; Jacobs SA; Robidoux A; Flynn PJ; Thirlwell MP; Fehrenbacher L; Stella PJ; Goel R; Julian TB; Provencher L; Bury MJ; Bhatt K; Geyer CE; Swain SM; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2015 Jan; 149(1):163-9. PubMed ID: 25542269
[TBL] [Abstract][Full Text] [Related]
82. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
Gillenwater HH; Stinchcombe TE; Qaqish BF; Tyann M; Hensing TA; Socinski MA
Lung Cancer; 2005 Mar; 47(3):413-9. PubMed ID: 15713525
[TBL] [Abstract][Full Text] [Related]
83. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
[TBL] [Abstract][Full Text] [Related]
84. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.
Chen XS; Nie XQ; Chen CM; Wu JY; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Ann Oncol; 2010 May; 21(5):961-7. PubMed ID: 20211870
[TBL] [Abstract][Full Text] [Related]
85. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Daz M; Miró C; Lobo F
Semin Oncol; 2004 Apr; 31(2 Suppl 5):31-6. PubMed ID: 15199530
[TBL] [Abstract][Full Text] [Related]
86. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
87. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
Kurozumi S; Yamaguchi Y; Matsumoto H; Kurosumi M; Hayashi SI; Fujii T; Horiguchi J; Shirabe K; Inoue K
PLoS One; 2019; 14(5):e0217279. PubMed ID: 31112577
[TBL] [Abstract][Full Text] [Related]
88. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
[TBL] [Abstract][Full Text] [Related]
89. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
[TBL] [Abstract][Full Text] [Related]
90. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
91. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Salvador J; Manso L; de la Haba J; Jaen A; Ciruelos E; de Villena MC; Gil M; Murias A; Galan A; Jara C; Bayo J; Baena JM; Casal J; Mel JR; Blancas I; Sanchez Rvira P
Clin Transl Oncol; 2015 Feb; 17(2):160-6. PubMed ID: 25119930
[TBL] [Abstract][Full Text] [Related]
92. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
[TBL] [Abstract][Full Text] [Related]
93. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
[TBL] [Abstract][Full Text] [Related]
94. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
Murad AM; Guimarães RC; Aragão BC; Scalabrini-Neto AO; Rodrigues VH; Garcia R
Am J Clin Oncol; 2001 Jun; 24(3):264-8. PubMed ID: 11404498
[TBL] [Abstract][Full Text] [Related]
95. Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Zhang J; Gay HA; Russo S; Parent T; Aljumaily R; Walker PR
Lung Cancer; 2014 Jan; 83(1):67-72. PubMed ID: 24246506
[TBL] [Abstract][Full Text] [Related]
96. Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.
Serrano MJ; Sánchez-Rovira P; Algarra I; Jaén A; Lozano A; Gaforio JJ
Jpn J Cancer Res; 2002 May; 93(5):559-66. PubMed ID: 12036452
[TBL] [Abstract][Full Text] [Related]
97. Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Budman DR; Calabro A; Rosen L; Lesser M
Anticancer Drugs; 2012 Mar; 23(3):272-9. PubMed ID: 23427335
[TBL] [Abstract][Full Text] [Related]
98. The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.
Gudur RA; Bhosale SJ; Gudur AK; Kale SR; More AL; Datkhile KD
Asian Pac J Cancer Prev; 2024 Jun; 25(6):1977-1986. PubMed ID: 38918659
[TBL] [Abstract][Full Text] [Related]
99. NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy.
Al Shboul S; El-Sadoni M; Alhesa A; Abu Shahin N; Abuquteish D; Abu Al Karsaneh O; Alsharaiah E; Ismail MA; Tyutyunyk-Massey L; Alotaibi MR; Neely V; Harada H; Saleh T
Sci Rep; 2023 Sep; 13(1):15903. PubMed ID: 37741850
[TBL] [Abstract][Full Text] [Related]
100. A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study.
Sharma S; Hiran KR; Pavithran K; Vijaykumar DK
World J Surg Oncol; 2009 Mar; 7():35. PubMed ID: 19331661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
